瀛晟科學(00209.HK)借入500萬元貸款
瀛晟科學(00209.HK)公佈,第三方張羣英同意按每月2.5%利率向全資附屬億豪集團授出500萬元的貸款,爲期一年。貸款抵押品包括借款方向貸款方提供出售公司已發行股本40%的股份抵押;和出售公司欠借款方的本金爲604.61萬元的股東貸款及其應計利息的轉讓契據。
出售公司主要業務爲投資控股,由張羣英擁有60%及由億豪集團擁有40%,並全資擁有忠勝,忠勝爲瀛晟科技全部股權之擁有人。
雙方同意取消貸款方根據出售協定授予借款方的回購期權,並借款方已向貸款方授予貸款方的認購期權,要求借款方於認購期權期內向貸款方或其指定代名人出售銷售股份及銷售貸款,現金代價爲1,000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.